<div id="readability-page-1"><p>Brummer Multi Strategy AB bought a new position in shares of  Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  bought 457,707 shares of the company's stock, valued at approximately $1,488,000. Maravai LifeSciences makes up  approximately  9.0% of Brummer Multi Strategy AB's portfolio, making the stock its 6th largest position. Brummer Multi Strategy AB owned about 0.18% of Maravai LifeSciences as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Maravai LifeSciences</strong> alerts:</span></p></div><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Tejara Capital Ltd raised its holdings in  Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company's stock worth $7,041,000 after acquiring an additional 511,992 shares in the last quarter.  Monaco Asset Management SAM raised its holdings in  Maravai LifeSciences by 315.0% during the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter.  First Eagle Investment Management LLC acquired a new position in  Maravai LifeSciences during the third quarter worth approximately $1,294,000.  Royce &amp; Associates LP increased its position in  Maravai LifeSciences by 38.0% during the third quarter. Royce &amp; Associates LP now owns 1,761,764 shares of the company's stock worth $5,056,000 after buying an additional 484,908 shares during the last quarter.  Finally, General American Investors Co. Inc. acquired a new position in  Maravai LifeSciences during the third quarter worth approximately $391,000. Institutional investors own  50.25% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts have weighed in on MRVI shares. Deutsche Bank Aktiengesellschaft  reissued a &#34;buy&#34; rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday. Wells Fargo &amp; Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an &#34;overweight&#34; rating in a research report on Friday. Finally, Wall Street Zen raised Maravai LifeSciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, February 28th. Four equities research analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $5.70.</p><p><b>View Our Latest Analysis on Maravai LifeSciences</b></p><h2>Maravai LifeSciences Stock Performance</h2><p>Shares of NASDAQ:MRVI opened at $4.85 on Monday. The company has a market capitalization of $1.25 billion, a P/E ratio of -6.83 and a beta of 0.62. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.95 and a 1 year high of $4.95. The company has a debt-to-equity ratio of 0.85, a current ratio of 6.60 and a quick ratio of 5.69. The business's 50 day simple moving average is $3.33 and its 200 day simple moving average is $3.39. </p><p>Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.29% and a negative net margin of 51.07%. On average, research analysts anticipate that  Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current fiscal year. </p><h2>About Maravai LifeSciences</h2> (Free Report)<p>Maravai LifeSciences Holdings, Inc <span>NASDAQ: MRVI<span></span></span> is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.  </p><p>Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Maravai LifeSciences</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Maravai LifeSciences Right Now?</h2><p>Before you consider Maravai LifeSciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.</p><p>While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MRVI

IBBQ

LABU

<p>Brummer Multi Strategy AB acquired 457,707 shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during Q4, valued at approximately $1.49 million, making it the 6th largest position in their portfolio. Other institutional investors have also increased their stakes in Maravai. Analysts have a consensus rating of "Moderate Buy" for MRVI, with a price target of $5.70. Maravai reported a quarterly EPS of $0.01, exceeding estimates, and had a revenue of $65.84 million. The stock opened at $4.85, with a market cap of $1.25 billion.</p>

Market Beat

Maravai LifeSciences

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Deutsche Bank AG

Wells Fargo

NVIDIA

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

NVIDIA Corporation

457,707 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Purchased by Brummer Multi Strategy AB